Technology Portfolio
Four platforms, four different levels of evidence, one operating model. Aybar Ecotechnologies develops technology to the point where an established operator can take it into manufacturing, registration, and market. We license, co-develop, and take equity. We do not manufacture.
Each entry below states what is proven, what is developed, and what is still being proven. That distinction is the whole point of this page.
Energy & Mobility
- Prototype stage
- Patent pending
- NDA-secured negotiations
Gravitational Modulation Platform
Laser-based gravitational field control for levitating transport, low-energy lift systems and aerospace propulsion. Designed for OEM integration, and addressed at the level of the physics rather than the mechanism.
Technical highlights
- Modular, surface-integrated architecture
- Grounded in the EMG Theory of the Photon, published 1992
- Prototype stage, core mechanism patent-pending
Commercial applications
Aerospace launch assist; levitation-enabled mobility without fixed magnetic infrastructure; gravity-driven power generation; construction, mining and telecom deployment in terrain-inaccessible locations.
Investor & partner opportunities
OEM licensing and development capital to move from prototype to demonstrator. Technical detail beyond the public page is shared under NDA.
Biotech
- Validated on enzymes
- Industrial pilot pending
Proprietary Protein Purification Protocol
Purification is 50% to 80% of the production cost of a therapeutic protein. The Aybar Protocol compresses it into a single chromatography step, on the FPLC and HPLC infrastructure producers already own.
Technical highlights
- 80–90% reduction in buffer use; 8–10× lower dilution
- Elution in 1–3 column void volumes, against 30
- Column regeneration in 3 hours, against several days
- Semi-continuous and programmable; no new capital equipment
Commercial applications
Functional food ingredients, nutraceuticals, therapeutic proteins and plant-based proteins. Addressable market above $700B across those segments; the purification consumables and services market alone is $19B.
Investor & partner opportunities
Volume-based licensing, purification-as-a-service, and joint ventures with ingredient firms. We will run the protocol on one of your protein products at no cost, given starting material and facility access.
Health
- Dental: clinically validated
- Granted: Japan, Mexico
- Pending: United States
- Medical & veterinary: in development
Universal Bactericide Platform
Lysozyme, a chelation system and a pH-stabilized formulation, active against gram-positive and gram-negative bacteria through a mechanism that does not apply the selective pressure antibiotics do, and therefore does not breed resistance.
Evidence by application
- Dental: clinically validated in humans, under bioethical approval
- Medical and veterinary: developed and investigated, not represented as clinically validated
- Respiratory: largest opportunity, least developed; seeking clinical partners
Intellectual property
One family from a single May 2020 international filing. JP 7768769 granted 4 November 2025. MX 433331 granted 23 March 2026, in force to 28 May 2040. US 2022/0362354 A1 published, application pending.
Investor & partner opportunities
Licensing and co-development with partners able to develop, register, manufacture and commercialize. Phase 1 market entry is an oral chewable under DSHEA. Full dossier under NDA.
Biofuel
- Laboratory scale proven
- Demonstration plant sought
CS-Ethanol Technology
Cellulosic ethanol has never failed for lack of feedstock. It has failed on process economics. This route hydrolyses the sugar polymers enzymatically, recovers the lignin as fuel, and leaves practically no inhibitory by-products behind.
Technical highlights
- About 99% hemicellulose conversion on both feedstocks
- Lignin recovered as fuel at roughly 22,000 Btu/kg
- Solvent and cellulolytic enzymes recovered and recycled
- Low energy consumption and low equipment investment
Commercial applications
Sugar mills, corn and rice processing, and any operation where lignocellulosic residue already accumulates in volume at a fixed location. The feedstock is agricultural waste, so it does not compete with food production for land.
Investor & partner opportunities
We are seeking a partner to install a demonstration plant and complete the development process. Laboratory results need confirmation at scale, and that gap is exactly where cellulosic ethanol projects have historically failed.
Licensing & partnerships
Work with us on what comes next
Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.